Patent 10,544,224 (US) Claim-By-Claim Analysis and Nivolumab HPV+ SCCHN Patent Landscape
US Patent 10,544,224 claims methods for treating HPV-positive head and neck squamous cell carcinoma (SCCHN) with a fixed, weight-independent 480 mg nivolumab dosing regimen administered once every four weeks. The claim set is built around (i) patient selection defined by HPV positivity and optional biomarker and subtype definitions, (ii) a dosing schedule that is explicitly “flat dose” and “without regard for the weight” of the subject, and (iii) optional clinical-outcome framing (overall survival at least ~10 months) and optional combination therapy with other anti-cancer agents (including CTLA-4 blockade). From a freedom-to-operate perspective, the enforceable core is likely the combination of HPV-positive SCCHN selection plus the specific fixed 480 mg Q4W nivolumab regimen; the additional dependent limitations (p16 staining thresholds, PD-L1 expression, protein panels, HPV subtypes, and combination/pretreatment context) narrow scope and can materially affect infringement risk for competitors.
What does US 10,544,224 claim and where is the enforceable “core” in the independent claims?
Claim 1: What is the tightest independent infringement hook?
Claim 1 requires all elements:
- Indication: “human papilloma virus (HPV)-positive squamous cell carcinoma head and neck cancer (SCCHN)”
- Therapy: administering nivolumab
- Dose form and dosing rule: flat dose of 480 mg and once every four weeks
- Weight rule: without regard for the weight of the subject
Practical claim construction themes
- The “flat dose” and “without regard for weight” language targets fixed dosing rather than weight-based dosing. This distinction matters if competitors use mg/kg regimens or different fixed dose schedules.
- The “HPV-positive SCCHN” limitation means HPV status is a gating element. Methods that treat HPV-negative disease with the same regimen are not covered by this claim as written.
- The claim does not require PD-L1 status, p16 staining percentage, or HPV subtype to be present in Claim 1; those appear in dependent claims.
Claim 2: Does adding HPV measurement change infringement risk?
Claim 2 depends on the method concept but adds an explicit two-step workflow:
- Measuring a level of HPV in a sample and confirming HPV-positive
- Administering flat dose 480 mg nivolumab once every four weeks, without regard to weight
Why this can matter
- If a competitor prescribes nivolumab for a patient already known to be HPV-positive from prior testing, the question is whether the competitor “measures” HPV as part of the method step. Claim 2 is more workflow-specific than Claim 1.
- Claim 1 can still capture treatment regardless of when HPV status was established, since it does not require the act of measuring.
Bottom line on core
- Most defensible infringement theory: HPV-positive SCCHN treated with nivolumab 480 mg Q4W fixed dosing.
- Most workflow-specific: the additional “measuring HPV in a sample” requirement in Claim 2.
Which dependent claim limitations narrow scope and how do they affect design-around strategies?
Claim 3 and 4: HPV-derived protein expression and immunohistochemistry panel
Claim 3: requires tumors expressing HPV-derived proteins or nucleic acid sequences encoding those proteins.
Claim 4: specifies exemplary proteins: p16, Ki-67, Cyclin D1, p53, ProEx C, E6, E7.
Impact
- These limitations narrow coverage to patients whose tumors exhibit or encode these markers.
- A design-around could be to select patients using different biomarker criteria not meeting these protein-defined limitations. However, as dependent claims, these are not required for Claim 1 or Claim 2 infringement.
Claim 5: HPV subtype list
Claim 5 enumerates HPV subtypes: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 (or combinations).
Impact
- If competitors treat HPV-positive SCCHN where the subtype is outside this list, infringement of this dependent claim may be avoided.
- But Claim 1 and Claim 2 still cover “HPV-positive” without restricting subtypes, so this is not a full escape unless HPV status is disputed or treatment avoids the overall claim scope.
Claim 6: p16 IHC staining threshold
Claim 6 requires > about 70% of tumor cells showing strong diffuse nuclear and cytoplasmic staining by p16 immunohistochemistry.
Impact
- This is a meaningful narrowing element for dependent coverage.
- In jurisdictions and trials, p16 positivity thresholds often drive HPV assignment. If a clinical protocol uses a lower threshold or a different interpretive method, infringement of Claim 6 is less likely.
Claim 7 and 19: PD-L1 expression
Claim 7: tumor further expresses PD-L1.
Claim 19 repeats PD-L1 as a dependent limitation.
Impact
- PD-L1-dependent criteria narrow coverage.
- If treatment decisions are made on HPV positivity without enforcing PD-L1 expression, Claim 7 is not needed for Claim 1/2 infringement.
Claim 8 and 14: overall survival at least ~10 months
Claim 8: overall survival at least about 10 months after administration.
Claim 14: same limitation tied to Claim 2.
Impact
- Outcome-based method claims are often litigated around measurement windows, causation, and whether the method “results in” the required clinical outcome for the treated subject.
- A competitor can still infringe the dosing and indication method steps even if individual outcomes vary. The inclusion of an OS floor mainly narrows and complicates enforcement.
Claim 9-13: combination therapy and prior ineffective therapy
Claim 9: “one or more additional anti-cancer agents” alongside nivolumab.
Claim 10: at least one additional agent is selected from:
- CTLA-4 binding antibody/antigen-binding portion that inhibits CTLA-4 activity
- chemotherapy
- platinum-based doublet chemotherapy
- tyrosine kinase inhibitor
- anti-VEGF inhibitor
- or combinations of these
Claim 11: subject received anti-cancer agents prior to nivolumab.
Claim 12: those prior agents were not effective in treating the tumor.
Claim 13: prior agents include platinum-based therapy.
Impact
- These dependent claims create a ladder of narrower combinations:
- “combination with additional agents” (Claim 9)
- specific classes including CTLA-4 (Claim 10)
- “prior therapy not effective” (Claims 11-12)
- “prior platinum therapy” (Claim 13)
- A competitor can reduce exposure by using nivolumab monotherapy in HPV+ SCCHN, or by using combination regimens that do not include the enumerated agent categories, or by treating after effective prior therapy (affecting “not effective” limitation).
What clinical and regulatory context is implicated by the “480 mg Q4W” fixed-dose nivolumab language?
The fixed-dose and dosing interval are central. Many nivolumab regimens in practice and trial literature historically shifted between weight-based and fixed dosing models depending on formulation labeling and regimen. US 10,544,224’s phrasing explicitly requires:
- a 480 mg flat dose, and
- once every four weeks, and
- no weight-based adjustment
This combination is typically aligned with fixed dosing strategies rather than mg/kg approaches.
Which infringement theories align with these claim elements?
- Direct performance: administering nivolumab 480 mg Q4W to an HPV-positive SCCHN patient is a straightforward infringement fit for Claim 1.
- Workflow infringement: performing HPV testing as a step as part of the method supports Claim 2’s added “measuring HPV in a sample” element.
- Contingent infringement: if the clinic additionally documents p16 ≥70% diffuse staining, PD-L1 expression, or specific protein panels, dependent claims may be asserted, but those are narrower.
How does this patent compare with generic and biosimilar risk: what do the fixed-dose claims mean for challengers?
Generic small-molecule risk
Nivolumab is a monoclonal antibody. “Generic” refers to biosimilar approaches in the US system, not small-molecule generics.
Biosimilar risk
A biosimilar that is used to treat HPV-positive SCCHN with the same 480 mg Q4W fixed dosing could still implicate method claims if the claims are not limited to the “nivolumab” brand entity versus the active moiety. The claims as provided are written with “nivolumab” dosing; in litigation, the question becomes whether “nivolumab” is interpreted as the mAb active ingredient (which biosimilars often target) or as a product-specific label reference.
Design-around levers for market entrants
- Dose-and-interval change: switching away from 480 mg Q4W would reduce Claim 1/2 risk.
- Weight-based dosing: moving to mg/kg dosing would violate the “flat dose … without regard for weight” requirement.
- Indication carve-out: targeting HPV-negative or non-SCCHN head-and-neck disease would avoid the “HPV-positive SCCHN” limitation.
- Patient selection and measurement process: avoiding a “measuring HPV level in a sample” step may mitigate Claim 2 but not Claim 1.
- Biomarker threshold reduction: avoiding p16 ≥70% diffuse IHC as part of patient selection may limit dependent claim scope.
What is the patent landscape around HPV+ SCCHN immunotherapy with nivolumab (and how does that affect enforcement likelihood)?
US 10,544,224 is one layer in a broader set of patent categories typically surrounding:
- PD-1/PD-L1 pathway antibodies (including nivolumab)
- HPV-associated biomarker stratification (often p16 IHC and HPV testing)
- fixed-dosing or dosing regimen strategies (interval and amount)
- combination therapy regimens (CTLA-4 combinations and chemo/targeted additions)
- treatment-line definitions and prior therapy status
Where 10,544,224 sits in the typical hierarchy
- Indication and biomarker gating: “HPV-positive SCCHN” and optional p16/PD-L1/protein panel/subtypes
- Dosing regimen specificity: “flat dose 480 mg once every four weeks without regard to weight”
- Optional clinical framing: OS ≥10 months and combination therapy components
This structure is designed to capture standardized dosing practices while adding multiple dependent barriers to narrow claim scope if the primary dosing-and-indication hook is contested.
How strong are the claims as a patent estate against a dosing-based attack?
Claim strength drivers
- The independent claims are anchored to a specific and operational dosing regimen (480 mg Q4W fixed).
- The indication is also specific (HPV-positive SCCHN), reducing the chance the claim is rendered overbroad for unrelated cancers.
Potential pressure points (litigation relevance)
- Obviousness and regimen predictability: if fixed dosing and Q4W intervals were established prior art practice for nivolumab, the patent’s novelty may hinge on the specific “without regard to weight” implementation combined with HPV-positive SCCHN selection.
- Outcome limitations: OS ≥10 months appears in dependent claims; enforcing outcome-linked method claims can be harder when patient heterogeneity is high.
- Breadth of biomarker language: some dependent claims (protein expression/nucleic acid encoding) are conceptually broad; they can create claim clarity issues or obviousness challenges depending on prior art testing frameworks.
What generic entry risks exist for HPV+ SCCHN dosing using nivolumab 480 mg Q4W?
The main commercial exposure is a biosimilar entrant or marketer who intends to label and administer a product using:
- HPV-positive SCCHN treatment protocol
- nivolumab dosing at 480 mg Q4W fixed
- without weight-based adjustment
If those match Claim 1, the entrant’s risk is not just “indirect” marketing risk but also the risk of practicing method steps by prescribers and treating institutions.
The added workflow measurement in Claim 2 increases exposure where HPV testing is integrated into a dosing protocol.
What are the likely infringement mapping outcomes by competitor treatment pattern?
| Competitor practice pattern |
Claim 1 (HPV+ SCCHN + 480 mg Q4W fixed) |
Claim 2 (adds HPV measurement step) |
Key dependent claims potentially implicated |
| Treats HPV+ SCCHN with nivolumab 480 mg Q4W fixed dosing |
High |
Medium to High |
PD-L1, p16 threshold, protein panel, subtype, OS ≥10 months |
| Treats HPV+ SCCHN with nivolumab but uses weight-based mg/kg |
Low to none |
Low to none |
Dependent biomarker claims still depend on core dosing not being met |
| Treats non-HPV SCCHN with same dosing |
Low to none |
Low to none |
Depends on “HPV-positive” limitation |
| Treats HPV+ SCCHN with 240 mg Q2W fixed |
Low to none |
Low to none |
Does not meet “480 mg once every four weeks” |
| Uses 480 mg Q4W but avoids “measuring HPV in a sample” as part of method |
High |
Lower |
Dependent biomarker claims only if their additional limitations are satisfied |
| Uses combination therapy with CTLA-4 or chemo along with 480 mg Q4W |
High |
Medium |
Claim 9-13 dependent scope may be asserted if other enumerated criteria met |
| Treats post-platinum failure (prior therapy not effective) and uses 480 mg Q4W |
High |
Medium |
Claim 11-13 depend on “not effective” and platinum inclusion |
Key takeaways
- US 10,544,224’s enforceable core is the method of treating HPV-positive SCCHN using nivolumab 480 mg flat dose administered once every four weeks without regard to weight (Claims 1 and 2).
- Dependent claims add narrowing gates: HPV subtype list, p16 IHC ≥70%, PD-L1 expression, specific HPV-derived protein panels, OS ≥~10 months, and combination therapy and prior ineffective therapy.
- For competitive freedom-to-operate, the biggest risk lever is whether any entrant’s clinical protocol uses the exact 480 mg Q4W fixed dosing for HPV-positive SCCHN. Dose-and-interval deviation and weight-based dosing are the most direct design-arounds against Claims 1/2 as written.
FAQs
-
Can a biosimilar used for HPV+ SCCHN at 480 mg Q4W fixed dosing infringe US 10,544,224?
If the dosing and indication steps are practiced as claimed, method-claim exposure can arise even when the marketed product is biosimilar, depending on claim interpretation of “nivolumab.”
-
Does HPV status need to be measured at the time of treatment to infringe Claim 2?
Claim 2 requires “measuring” HPV in a sample as part of the method, so the infringement risk depends on whether that step is performed as claimed.
-
Is p16 ≥70% required for infringement?
No. p16 ≥70% is in a dependent claim (Claim 6). Claims 1 and 2 do not require the p16 threshold.
-
How does PD-L1 expression affect infringement?
PD-L1 appears in dependent claims (Claims 7 and 19). It is not required for Claim 1/2, but it can expand dependent-claim coverage.
-
Does the “overall survival at least ~10 months” limitation bar infringement if a patient survives less?
It narrows dependent claim coverage. Practice of the core dosing-and-indication steps still aligns with Claims 1/2 independent of OS in those independent claims.
